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Background: Preliminary placebo-controlled evidence paved the ground to the US Food and 
Drug Administration approval extension of lisdexamfetamine for the treatment of moderate-
to-severe binge eating disorder (BED) in adults.
Objectives: To provide a preliminary qualitative and quantitative synthesis of the placebo-
controlled, randomized clinical trials (RCTs) considering the efficacy and tolerability of lisdex-
amfetamine in the acute and/or maintenance treatment of moderate-to-severe BED in adults.
Methods: A preliminary, yet comprehensive, systematic review was performed by accessing 
a broad range of resources providing publicly available data about lisdexamfetamine at the 
time of inquiry (March 2016). Study eligibility criteria, participants, and interventions were 
considered focusing on major clinical and functional outcomes of either efficacy or tolerability 
of lisdexamfetamine in the treatment of moderate-to-severe BED in adults.
Results: Meta-analysis of data pooled from three acute RCTs significantly favored lisdex-
amfetamine over placebo in the reduction of binge eating days/week, Yale-Brown Obsessive 
Compulsive Scale Modified for Binge Eating total score, weight, response, and remission rates 
(all, P#0.01). In contrast, discontinuation rates due to treatment-emergent adverse events were 
significantly higher among patients in receipt of lisdexamfetamine (relative risk 2.19, P=0.04) 
versus placebo.
Limitations: Publication, selection, performance, attrition, reporting, sponsorship, and 
“diagnostic shift” biases. Lack of inclusion of adverse event effects other than those requiring 
discontinuation of the trial(s), as well as lack of information about clinically relevant psychiatric 
or other medical comorbidities, limits the overall generalizability of pooled results.
Conclusion: Across the included acute phase RCTs, lisdexamfetamine (at 30, 50, or 70 mg/day) 
led to significant reduction in a number of clinically relevant outcomes compared to placebo. 
Moreover, safety concerns related to adverse events, high discontinuation rates, and the need 
for additional long-term maintenance of RCTs solicit careful monitoring of the drug in terms 
of overall safety and tolerability by further RCTs.
Keywords: lisdexamfetamine, binge eating disorder, systematic review, meta-analysis
Introduction
Already enlisted by the Diagnostic and Statistical Manual for Mental Disorder Fourth 
Edition (DSM-IV)1 and its Text-Revision (DSM-IV-TR)2 as a provisional (“appendix B”) 
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category of “eating disorder (ED) not otherwise specified”, 
binge eating disorder (BED) is characterized by recurrent 
episodes of binge eating occurring in a discrete period of 
time (#2 hours), involving a sense of lack of control over 
the consumption of an amount of food that is definitely 
larger than most people would consume under similar cir-
cumstances. Lack of control over eating is a core feature of 
BED distinguishing it from overeating.3
BED lifetime prevalence among US adults approximates 
2.6%, which is higher than the one documented for anorexia 
nervosa and bulimia nervosa combined together, though sex 
distribution of BED is less skewed in comparison.4,5 In addition, 
while no racial group is significantly overrepresented,6 BED 
is traditionally documented to be more common among 
young obese individuals, who usually receive first diagnosis 
of BED early in life around mid-1920s,7,8 although no mini-
mum age threshold has been established for the diagnosis.9
Higher prevalence rates of BED would nonetheless be 
expected, both in UK10 and US community11 and clinical11 
samples. These higher figures would ultimately reflect a 
higher diagnostic sensitivity developed by the clinicians 
over the time, as well as the impact of more permissive 
criteria introduced by the Fifth Edition of the DSM (DSM-5),9 
finally acknowledging BED as a distinct diagnostic cat-
egory now characterized by reduced “frequency” (“once 
per week” instead of “twice per week”) and “duration” 
(“three months” vs “six months”) criteria compared to the 
DSM-IV ones.9,12,13
Many cases of BED may still go underdiagnosed for many 
years because patients seeking psychiatric treatment for either 
psychiatric or somatic disorders are not always specifically 
asked about their eating behavior.14 Earlier detection and 
optimal multidisciplinary, stepped-care approach to BED 
nonetheless represent primary needs, with a special emphasis 
toward a better pharmacological management.11,15–17
In this regard, many of the available pharmacological 
studies on BED have long been plagued by limitations such 
as small sample size, high placebo response and/or dropout 
rates, and limited generalizability of findings to real-world 
practice,18,19 with no conclusive advantage documented for 
any drug over alternative approaches, especially dietary, or 
cognitive behavioral therapy, just to name few.19
This is compelling, especially considering that various 
neurobiological underpinnings of BED primarily focusing on 
dopamine, opioid, acetylcholine, and serotonin neurocircuitry 
within brain reward regions have been advocated to play a 
role on the matter in both animal and human studies.19,20
To date, evaluated agents targeting neurotransmitter 
systems allegedly involved in motivated feeding behavior, 
mood regulation, and impulse control include several antide-
pressant and anticonvulsant agents that demonstrated efficacy 
in reducing binge eating frequency, but only in limited cases 
these effects have resulted in patients achieving abstinence, 
which would be the primary goal of the treatment; they also 
range from less (fluvoxamine) to more (topiramate) effective-
ness in achieving weight loss, though clinically meaningful 
and significantly greater than placebo for both drugs.19
Moreover, many individuals with BED receive 
pharmacotherapy21,22 in the absence of any US Food and 
Drug Administration (FDA)-approved drug,3,23 at least 
until early 2015, when the central nervous system (CNS)-
stimulant lisdexamfetamine dimesylate (hereafter referred 
to as “lisdexamfetamine”) was granted extended approval 
for the treatment of moderate-to-severe cases of BED in 
adults – but weight loss – beyond the 2007 sole approval of 
attention deficit hyperactivity disorder (ADHD).24
The present systematic review and exploratory meta-
analysis thus evaluated preliminary placebo-controlled 
evidence about the efficacy and safety of lisdexamfetamine 
in moderate-to-severe adult cases of BED.
Methods
Data source and search methods
The present systematic review adhered to the Preferred 
Reporting Items for Systematic reviews and Meta-Analyses 
(http://www.prisma-statement.org/),25 while meta-analysis 
adhered to the Meta-analysis Of Observational Studies 
in Epidemiology guidelines.26 We searched for English-
language published randomized clinical trial (RCTs) 
comparing lisdexamfetamine versus placebo for the treatment 
of moderate-to-severe BED in adults (both sexes). Eventual 
adjunctive therapies of lisdexamfetamine with any additional 
drug, physical therapy, or psychotherapy were also taken into 
account. Although our search strategy accounted for results 
indexed from inception until the writing time (March 2016), 
special emphasis was placed by two appointed authors 
(MF and LO) on those results indexed since January 2008, 
as these latter would reflect the recent DSM-5’s introduction 
of BED as an autonomous disorder, following hierarchical 
considerations17 and the notion that articles claiming BED 
inclusion in DSM-5 dated back to that time.27
The US National Library of Medicine’s PubMed resource 
(http://www.ncbi.nlm.nih.gov/pubmed/), the US ClinicalTrials.
gov registry (https://ClinicalTrials.gov/), the EU Clinical Trials 
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Register (https://www.clinicaltrialsregister.eu/), the Web of 
Science® (Thomson Reuters®), Scopus (Elsevier’s®) (http://
www.scopus.com/), EMBASE® (Elsevier’s®), CINAHL® 
(EBSCO Nursing Resource®) (https://www.ebscohost.com/
nursing/products/cinahl-databases/cinahl-complete), and 
PsycINFO® (American Psychological Association) (http://
www.apa.org/pubs/databases/psycinfo/) databases were 
inquired on March 1, 2016. Only “completed” placebo-
controlled RCTs with posted results were considered for 
inclusion in either the US or EU registers.
Publicly available press release materials, conference 
posters, and meeting abstracts posted at the website of the 
manufacturer of lisdexamfetamine (Shire®) were likewise 
accounted. The searched terms across different sources 
included: “lisdexamfetamine”, “lisdexamphetamine”, 
“SPD489” (Lisdexamfetamine dimesylate); “vyvanse” (®), 
“binge eating disorder”, “placebo-controlled clinical trial”, 
“open-label”, “moderate-to-severe”, “adults”, or their 
combination.
The adopted MEDLINE search string was: “(((((((((((((lis-
dexamfetamine) AND binge eating disorder) AND clinical 
trial) OR lisdexamphetamine) AND binge eating disorder) 
AND clinical trial) OR SPD489) AND binge eating) AND 
clinical trial) OR lisdexamfetamine) AND binge eating 
disorder) AND moderate) AND severe) AND adults”. Attempt 
to retrieve additional bibliographic references was made 
screening the reference list of the selected published studies and 
relevant review articles whenever available. We also planned 
into advance contact with the authors of proof-of-concept 
studies, Phase II, III, or IV RCTs if ever indexed, in order to 
gather additional information relevant to the research theme 
at study. The Cochrane Library (http://www.cochranelibrary.
com/) was also accessed aiming at detecting unpublished 
or negative results, thus striving to avoid any “sponsorship 
bias” as much as possible, as performed by inquiring the 
Journal of Pharmaceutical Negative Results (http://www.
pnrjournal.com/), the Journal of Negative Results – Ecology & 
Evolutionary Biology (www.jnr-eeb.org), and the Journal of 
Negative Results in Biomedicine (www.jnrbm.com). 
Finally, both auto- and hand-searches for “type-I” 
(“duplicates among/across different databases”) and “type-II” 
(“duplicate publications in different Journals/issues)28 were 
performed using Review Manager v 5.3™ for Microsoft 
Windows™.29 Documents focusing (only) on children or 
adolescents, ADHD trials, case reports/series, or preclini-
cal or otherwise incomplete or nonpublicly available data 
were excluded.
Outcome measures
Efficacy measures were “reduction in binge eating days/
week” from least square means with mixed effects model 
for repeated measures (MMRM) or from last observation 
carried forward, where MMRM data were not available, 
accounted as the primary outcome measure, while “reduction 
in the Yale-Brown Obsessive Compulsive Scale Modified 
for Binge Eating (YBOCS-BE)30 total score” was adopted 
as secondary efficacy measure.
Response rates across trials were defined by a Clinical 
Global Impressions (CGI) Improvement score31 of “very 
much improved” or “much improved”. Remission was 
defined by 4-week cessation of binge eating. Reduction in 
weight was also considered across documenting studies. 
Discontinuation rates because of treatment-emergent adverse 
events (TEAEs) were also regarded across reporting studies. 
The primary endpoint was “time to relapse of binge eating 
symptoms in adults with moderate-to-severe BED”. For 
maintenance studies, the primary outcome measure was “time 
to relapse of binge eating symptoms”; additional outcomes 
included “proportion of relapse vs placebo” at study endpoint, 
among other measures.
Additional qualitative results were recorded whenever 
documented across the included studies. Finally, though infor-
mative, positive predictive value and negative predictive value 
were not systematically recomputed nor presented herein as 
they were already extracted for most of the relevant RCTs,3 
but the latest available maintenance RCT32 and the notion that 
such Bayesian index could be misleading when preferred to 
effect size computations using meta-analytic approaches.33,34
Data analysis
We decided “a priori” to analyze data using a random effect 
model due to heterogeneity in study duration, phase of the 
trial, primary outcome measures and clinical samples, or dose 
of the drug. A random effect model incorporates both within- 
and between-study variance into the estimate of average 
treatment effects and is therefore appropriate when analyzing 
studies with methodological heterogeneity. The standard 
mean differences (SMDs) for continuous variables and rela-
tive risk (RR) for dichotomous outcomes were calculated 
with 95% confidence interval (CI) limit. The analyses were 
conducted using the Comprehensive Meta-analysis™ v 3 for 
Microsoft Windows™ software (Englewood, NJ, USA).35 
For those studies presenting results in the standard error of 
mean (SEM) form; standard deviation (SD) was converted 
to SEM using the formula: SD = SEM* √n, where n is the 
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sample size. Data were entered and/or extracted by three lead-
ing authors (MF, MS, and BS) assisted by additional authors 
(GP, DDB, LO, NV, and LG). Heterogeneity was assessed 
by the I2 statistic.36 For each pooled analysis, in order to test 
for publication bias, a trim and fill adjusted analysis was con-
ducted37 in order to remove the most extreme small studies 
from the negative or positive side of the funnel plot, and the 
effect size at each iteration was recalculated, until the funnel 
plot was symmetric about the (new) effect size.
Results
studies included in the analysis
Details about the multistep screening of results have been 
outlined in Figure 1. Stating the very preliminary nature of 
the present systematic review and meta-analysis, only four 
original studies met our inclusion criteria, including one 
preliminary maintenance report,32 a Phase II RCT,38 and two 
pivotal Phase III RCTs for which results were presented in a 
single report.39 The included acute-treatment RCTs recruited 
different samples of participants. Table 1 provides the details 
of the studies.
Qualitative synthesis of results
The results of the only preliminary maintenance study were 
made available to the public through the manufacturer’s 
press-release webpage.32 All the studies were multicenter 
trials sponsored by the drug manufacturer and conducted 
either in the USA or Germany (and Spain or Sweden for 
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Phase III trials). Anorexia nervosa, bulimia nervosa, ADHD, 
as well as other relevant psychiatric comorbidities or medica-
tions were shared exclusion criteria. All included trials based 
on the DSM-IV-TR2 criteria rather than the more permissive 
DSM-59 ones were made officially available after the regis-
tration of the studies.
Statistically significant reduction (P#0.01) in binge 
eating days/week (primary efficacy outcome across 
the included studies) were observed for lisdexamfet-
amine doses of 50 and 70 mg/day with large effect sizes 
in the three acute RCTs.38,39 Similarly, lisdexamfetamine 
proved statistically significant (P#0.01) superiority over 
placebo in the maintenance trial with regard to the primary 
endpoint “time to relapse of binge eating symptoms”.32 
Specifically, in the 11-week Phase II trial (protocol 
number: SPD489-208),38 the difference for lisdexamfe-
tamine versus placebo MMRM least square (LS) mean 
change from baseline to week 11 on log transformed binge 
eating days per week was (mean ± SEM) -0.01 (0.096), 
P=0.88; -0.26 (0.096), P=0.01; -0.35 (0.096), P,0.01 
for lisdexamfetamine doses of 30, 50, or 70 mg/day, 
respectively, favoring lisdexamfetamine doses of 50 and 
70 mg/day but not of 30 mg/day. In the acute-treatment 
12-week trials (protocol numbers: SPD489-343 and 
SPD489-344),39 the difference for lisdexamfetamine versus 
placebo MMRM LS mean change from baseline to week 
11 in binge eating days per week was -1.35 (1.7, -1.01), 
P,0.01 for study 1 (SPD489-343), with mean lisdexam-
fetamine dosage of 56.9+9.72 mg/day, and -1.66 (-2.04, 
1.28), P,0.01 with mean lisdexamfetamine dosage of 
57.6+9.24 mg/day in study 2 (SPD489-344).39
Pooled (30, 50, or 70 mg/day) “responders’ rates” as 
defined by a CGI-S improvement score of “very much 
improved” or “much improved” in the acute trials versus 
placebo were as follows: 89.6% versus 64.5%38 or 82.1% 
versus 47.3% (SPD489-343),39 or 86.2% versus 42.6% 
(SPD489-344),39 respectively.
Pooled “remission rates” versus placebo as defined by 
“4-week cessation of binge eating” in the acute-treatment 
trials were: 42.3% versus 21.3%38 or 40% versus 14.1% 
(SPD489-343)39 or 36.2% versus 13.1% (SPD489-344),39 
respectively.
Pooled “discontinuation rates” due to TEAEs were as fol-
lows: 3.6% versus 0%38 or 6.3% versus 2.7% (SPD489-343)39 
or 3.9% versus 2.7% (SPD489-344),39 respectively.
Any TEAE frequency was significantly higher in the lis-
dexamfetamine group compared with placebo; 84.7% versus 
58.7% (SPD489-208),38 82.3% versus 58.8% (SPD489-
343),39 77.3% versus 50.8% (SPD489-344).39 Moreover, 
one patient died due to methamphetamine overdose (in the 
SPD489-208 trial) though this event was considered unre-
lated to the trial itself,38,40 and severe adverse event (AE) 
frequency in the lisdexamfetamine group was equal to 
8.9% versus 3.2% (SPD489-343),39 and 3.9% versus 3.2% 
(SPD489-344).39
Concerning the Phase-III, 26-week maintenance placebo-
controlled RCT,32 lisdexamfetamine demonstrated superiority 
over placebo (P#0.01) with respect to the primary efficacy 
endpoint (“time to relapse”). Notably, the maintenance trial 
actually consisted of a 4-week screening period, a 12-week 
open-label treatment phase (4 weeks of dose optimization and 
8 weeks of maintenance), followed by a 26-week, double-
blind, randomized withdrawal phase and a follow-up visit 
1 week after the last on-treatment visit. Overall, 418 patients 
were included in the study; yet exact figures of those allo-
cated to either lisdexamfetamine (50 or 70 mg/day) rather 
than placebo were not publicly disclosed at the writing time. 
Similarly, during the randomized withdrawal phase, two 
patients receiving lisdexamfetamine experienced serious 
AEs (undisclosed at the writing time). The most commonly 
reported TEAEs (reported by 5% or more of the patients) 
leading to study discontinuation were documented in the 
prerelease report available to the public; yet exact propor-
tions were not disclosed at the writing time. Therefore, the 
quantitative extractions focused on the three acute-treatment 
trials, the results of which were made publicly available 
through two papers.38,39
Meta-analysis
Only the 11-week Phase II trial (protocol number: SPD489-
208)38 reported separate results for 30, 50, and 70 mg/day 
of lisdexamfetamine groups, which we analyzed together 
with data from the acute-treatment 12-week trials (protocol 
numbers: SPD489-343 and SPD489-344).39 Also, we could 
not include the maintenance trial in our meta-analysis since 
it had different primary outcomes (“time to relapse”). Thus, 
only three38,39 of four32,38,39 original studies included in the 
systematic review were also included in the quantitative 
analysis, as detailed in Table 2.
A total of 450 patients received placebo, and 583 patients 
were randomized to lisdexamfetamine, of whom 66, 65, 
and 65 patients were allocated to doses of 30, 50, and 
70 mg/day, respectively, versus 64 patients randomized to 
receive placebo in the 11-week Phase II trial.38
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Primary efficacy outcome: “change in 
binge eating days/week at study endpoint” 
across different dosages of the drug 
versus placebo
Lisdexamfetamine reduced days with binge eating sig-
nificantly more than placebo (studies =3, SMD =-0.56 
[-0.84, -0.28], P,0.01).
Quantitative synthesis of results: “change 
in cgi-s, YBOcs-Be scores, remission 
rates (‘4-week cessation of binge eating’) 
and mean weight reduction, in kg”
Change in YBOCS-BE scores statistically significantly 
differed among patients receiving lisdexamfetamine (any 
dose) versus placebo (P#0.01) in single studies and 
meta-analyzing all data together (studies =3, SMD =-0.77 
[-1.02, -0.52], P,0.01).
Comparisons of lisdexamfetamine (any dose) versus pla-
cebo showed significantly higher rates of response based on 
the CGI-S scores (studies =3, RR =1.58 [1.35, 1.84], P,0.01) 
and of remission (4-week binge cessation) (studies =3; 
RR =2.43 [1.95, 3.01], P,0.01). Mean weight reduction was 
significantly higher in lisdexamfetamine group compared with 
placebo (studies =3, SMD =-1.28 [-1.51, -1.06], P,0.01).
Quantitative synthesis of results: 
“discontinuation rates due to Teaes”
Discontinuation rates among patients receiving lisdexamfet-
amine – any dose – were significantly higher versus placebo 
(studies =3, RR =2.19 [1.03, 4.66], P=0.04).
Discussion
The present study has suggested some early and promising 
evidence supporting the efficacy of lisdexamfetamine, a 
cost-effective treatment for moderate-to-severe BED adults 
in the USA.41 This encouraging evidence was consistent 
across all the primary and secondary outcomes accounted 
in the included acute-trials (meta-analysis) and also the 
maintenance trial (systematic review). However, TEAEs and 
subsequent discontinuation rates were significantly higher 
among those patients receiving lisdexamfetamine.
Main results and major implications 
for the clinical practice
Overall, the days with binge behavior, the response, and 
remission rates indicate solid and consistent efficacy profile T
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of lisdexamfetamine in BED; however, these results should 
be considered as preliminary. Moreover, the Y-BOCS-BE 
scale provides an accurate measuring of the binge eating 
behavior. A significant reduction in its total scores for those 
patients allocated to 50 or 70 mg/day lisdexamfetamine rather 
than placebo is therefore clinically meaningful. Similarly, 
since most bingers might be overweight patients, the occur-
rence of a significant weight reduction with lisdexamfetamine 
versus placebo is also clincially relevant, although it must 
be remarked that lisdexamfetamine is not FDA-approved 
for weight reduction/control at the writing time and that 
overweight or frank obesity is not included among the 
DSM-5 codes.
This latter consideration has further major clinical impli-
cations, especially considering that CNS stimulants may be 
abused by overweight people, regardless the presence of full-
threshold binge eating behavior42–44 and that, to some extent, 
weight loss would be a side effect for some other patients 
rather than a treatment benefit. The presence of cardiometa-
bolic illness further increases the risk of pulmonary hyperten-
sion among people receiving CNS stimulants.45 Insomnia is 
also a common side effect associated with CNS stimulants.46 
While the AEs documented in the studies included in the 
present systematic review (three acute-treatment trials and 
one maintenance RCT) were not life-threating ones, not 
even leading to trial discontinuation, additional investiga-
tions about the acute- and maintenance-treatment safety 
and tolerability of lisdexamfetamine are warranted, despite 
preliminary evidence on the matter would be consistent with 
the overall safety profile documented among ADHD patients 
exposed to comparable doses of the drugs (at least in the acute 
setting). Long-term/maintenance trials are definitely needed 
(one ongoing trial at the writing time: NCT01657019). This 
is not just with reference to placebo comparisons, but also 
versus other drugs often prescribed as off-label treatment of 
moderate-to-severe BED in adults, including the pro-drug 
methylphenidate as well as the non-CNS stimulant antide-
pressant drugs (ie, fluoxetine or bupropion).
Finally our results bring attention on safety aspects of 
lisdexamfetamine, which should be carefully evaluated by 
further long-term studies, ideally including also adolescent 
and old age subjects.40 In addition, studies conducted by 
independent researchers and not funded by the manufacturer 
would help reduce any potential bias.
Limitations of the study
Though informative, the present review and meta-analysis 
only included four original studies, of which only three were 
suitable for pooled quantitative extraction. Nonetheless, it must 
be remarked that as little as two studies should be acceptable 
for a preliminary meta-analytic report, even when accounting 
for heterogeneous active compounds in the same class of 
drugs and/or differential doses,47 whereas those meta-analysis 
accounting for substantially heterogeneous compounds and/or 
based on incomplete sources would not be informative, not 
even if including a high number of studies.48 Moreover, we 
acknowledge that meta-analyses with ,20 studies have 
limited power to detect publication bias.49
Specifically, the present systematic review actually 
included three homogenous acute-treatment studies and one 
additional maintenance study. Yet, only selected outcomes/
moderators documented for the acute-treatment trials could 
be pooled together since both the operational criteria and 
exact prevalence rates of efficacy or safety measures in the 
maintenance phase were either undisclosed at the writing 
time or presented as a mean of the double-blind plus the 
open-label phase. Inclusion of pooled number obtained by 
open-label phases too were thus avoided in order to ensure 
consistency of quality of the pooled results.
Concerning additional potential biases, the acknowledg-
ment of BED as a full diagnostic category by the DSM-5 and 
greater attention by clinicians toward the burden associated 
with BED most likely also lead to increased attention of the 
brands toward the pharmacological management of such 
condition. Nonetheless, the FDA extended the approval of lis-
dexamfetamine also for the treatment of moderate-to-severe 
BED in adults24 based on DSM-IV-TR2 rather than the more 
permissive DSM-59 criteria. Moreover, the FDA extended 
approval based on two Phase III studies39 and one Phase II 
study38 sharing similar entry criteria, all indicating superiority 
of lisdexamfetamine over placebo,23,40 as confirmed by pre-
liminary number needed to treat and to harm data computed 
owing to the primary outcome “binge-eating days/week” of 
FDA-accounted placebo-controlled acute-treatment clinical 
trials.50 The encouraging results from a Phase III maintenance 
RCT32 (and its 12-week open-label safety extension study) 
would also be evaluated by the FDA for potential inclusion 
of these data to the current labeling of the drug.
From this perspective, we submit that the FDA approval 
of lisdexamfetamine as the first drug for the treatment of 
moderate-to-severe BED in adults should not be perceived 
as the mere consequence of “marketing strategy” taking 
advantage of a “diagnostic shift” or placebo-controlled 
“publication bias” related to existing drugs. Yet, we were 
unable to find any negative result trial or any eventual hint 
of potential “sponsorship bias” at the present time.
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Nonetheless, 1) a selection bias due to inadequate genera-
tion of randomized sequence, 2) inadequate concealment of 
allocation prior to assignment, 3) performance bias due to 
knowledge of the allocated interventions by participants and 
personnel during the studies, 4) attrition bias due to amount, 
nature, or handling of incomplete outcome data, 5) reporting 
bias due to selective outcome reporting, and 6) substantial 
lack of inclusion of AEs other than those requiring discontin-
uation of the trial may all have undermined the quality of the 
original studies in the accounted review and meta-analysis, 
ultimately further stressing out the need for additional, well-
designed, replication studies on the matter beyond those 
already undertaken by the drug manufacturer.
Conclusion
While the preliminary data suggest that lisdexamfetamine 
would have promising efficacy in CGI-S-defined response 
and in remission rates, as well as in reducing overall days 
with binge, weight and total Y-BOCS-BE scores, additional 
acute and especially maintenance-phase trials are warranted, 
whereas current evidence in support of safety of lisdex-
amfetamine in the acute treatment of moderate-to-severe 
BED in adults is tentative, but also unclear, thus urging for 
systematic controlled long-term assessment and monitoring. 
Since AEs and discontinuation rates were higher among 
patients receiving lisdexamfetamine rather than placebo, 
future independent research is urged to clarify the reliability 
of preliminary safety results made publicly available after 
sponsored trials.
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